Skip to main content

Assignment and Request for Agency Component Designation for Premarket Applications (21CFR Part 3.1-3.10)

BayBiotech.NET
The main purpose of 21 CFR Part 3 is to support the efficiency of agency management and operations by providing guidelines for determining the agency component that will have primary jurisdiction for any drug, device, or biological product or providing the guidelines for the agency component determination where such jurisdiction is unclear. Out of 10 sections of the 21CFR Part 3 (Product Jurisdiction), the blog has the main emphasis on Sec 3.5 and 3.7 that relates to the guidance documents for agency designations as well as the requirements for request of agency designation in case the designation is unclear as per the guidance.
As per Sec 3.5, The Center for Biologics Evaluation and Research, the Center for Devices and Radiological Health, and the Center for Drug Evaluation and Research have developed guidance documents clarifying product jurisdictional issues. The guidance documents entitled "Intercenter Agreement Between the Center for Drug Evaluation and Research and the Center for Devices and Radiological Health;" "Intercenter Agreement Between the Center for Devices and Radiological Health and the Center for Biologics Evaluation and Research;" "Intercenter Agreement Between the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research." are available in the Division of Dockets Management (HFA-305), Food and Drug Administration. These guidance documents describe the responsibility for categories of products or specific products.
The sponsor of a premarket application filing for a combination or other product covered by these guidance documents may contact the designated agency component identified in the intercenter agreement before submitting an application of premarket review or to confirm coverage and to discuss the application process.
For a combination product not covered by the guidance document or for a product where the agency component with primary jurisdiction is unclear or in dispute, the sponsor of an application for premarket review should follow the procedures described in Sec 3.7 to request a designation of the agency component with primary jurisdiction before submitting the premarket application.

For filing the designation request, an original and two copies of the request for designation are required with a page limit of 15 pages, including attachments, and must have the detailed identity of the sponsor and the product. If any component of the product has already received the premarket approval the Identification of such a component must be included in the designation request letter.
In the request for designation, the sponsor's are encouraged to provide with the recommendation as to which agency should have primary jurisdiction based on the mode of action that provides the most important therapeutic action of the combination product. If the sponsor is unable to determine, then the recommendation must be based on the assignment algorithm provided in section 3.4(b).
For further details about the Product Jurisdiction follow the link. Rest will follow….

Comments

Popular posts from this blog

Good Machine Learning Practices

BayBiotech.NET A joint effort by FDA,  United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) and Health Canada have developed guiding principles to help promote utilization of medical devices that are safe and effective and utilize artiificial intelligence and machine learning. To find out more details check out the link here!

Group C (Treatment IND) Drugs

BayBiotech.NET Since 1976, National Cancer Institute (NCI) in agreement with FDA has established the Group C classification system to allow access to certain drugs for the cancer patients specifically falling under a category that adequate alternative therapy or if the available alternative therapy has significant toxic effects. Each Group C drug protocol specifies patient eligibility and drug use information. Group C drugs are provided only to properly trained physicians who have registered themselves with NCI using a special form to assure that their patient qualifies under guidelines - or protocols - for the drug. Physicians using drugs under Group C have no reporting requirements to the NCI other than the obligation to report adverse drug reactions. Group C drugs are provided free of charge, and the Centers for Medicare and Medicaid Services provides coverage for care associated with Group C therapy. Making Group C drugs available to the critically ill patients not only provi...

Food Safety Bill: A major overhaul of the Food Safety System

BayBiotech.NET The recently passed Food Safety bill is being considered to be a major overhaul of the food safety system in the United States and is considered to change the mission of the FDA, focusing it on preventing food-borne illnesses rather than reacting after an outbreak occurs. Under this legislation, food manufacturers are required to examine their processing systems to identify possible ways that food products can become contaminated and to develop detailed plans to keep that from happening. Companies must share those plans with the F.D.A., and provide the agency with records, including product test results, showing how effectively they carry them out. To read more about it follow the link